1. US Food and Drug Administration. 2006. Guidance for industry. Q9 quality risk management. Accessed November 1, 2010, at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073511.pdf.
2. US Food and Drug Administration. 2009. Guidance for industry. Q10 pharmaceutical quality system. Accessed November 1, 2010, at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073517.pdf.
3. US Food and Drug Administration. 2004. Guidance for industry. PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Accessed November 1, 2010, at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070305.pdf.
4. US Food and Drug Administration. 2006. Guidance for industry. Q8(R2) pharmaceutical development. Accessed November 1, 2010, at: http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm073507.pdf.
5. CMC Biotech Working Group. 2009. A‐Mab case study. Accessed November 1, 2010, at: http://www.casss.org/associations/9165/files/A‐Mab_case_study_Version_2‐‐1.pdf.